Computational screening of FDA-approved hepatitis c drugs for inhibition of VEGFR2 in liver cancer
Liver cancer (LC) is one of the most common tumours and the leading cause of cancer-related death globally. Amidst the problems associated with existing treatments, such as hepatotoxicity, recurrence, drug resistance, and other adverse effects, researchers are under pressure to find alternatives. To...
Saved in:
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
2024
|
Subjects: | |
Online Access: | http://umpir.ump.edu.my/id/eprint/43151/1/Computational%20Screening%20of%20FDA-Approved%20Hepatitis%20C.pdf http://umpir.ump.edu.my/id/eprint/43151/ https://doi.org/10.1002/slct.202402683 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|